Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0VHVOA)
| ADC Name |
TUB-030
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
TUB-030
Click to Show/Hide
|
|||||
| Organization |
Tubulis (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-5T4 antibody
|
Antibody Info | ||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
P5 (PEG24)-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
tubutecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Lung cancer | ||||
| Head and neck cancer | ||||
| Unspecific solid tumor |
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (≥18 years, ECOG 0-1) had adequate organ function, measurable disease per RECIST v1.1, and resolved prior treatment toxicities (≤grade 1). Exclusions included recent anticancer therapy (<4 weeks/5 half-lives), uncontrolled brain metastases, or inadequate contraception. WOCBP required highly effective contraception during and post-treatment (5 half-lives + 6 months).
Click to Show/Hide
|
||||
| Administration Dosage |
A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06657222 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01) | ||||
| Primary Endpoint |
The MTD was defined as the highest dose where ≤1 of 3 patients experienced DLTs per NCI CTCAE v5.0, assessed from enrollment until 30 days post-treatment.
|
||||
| Other Endpoint |
Safety outcomes included AE incidence, PK parameters (Cmax, Cmin, Tmax, AUC, T1/2), immunogenicity (anti-TUB-030 antibodies), and efficacy (ORR per RECIST 1.1), all evaluated until 30 days post-treatment.
|
||||